Offerings |
Jun. 04, 2026
USD ($)
shares
|
|---|---|
| Offering: 1 | |
| Offering: | |
| Fee Previously Paid | false |
| Other Rule | true |
| Security Type | Equity |
| Security Class Title | Sarepta Therapeutics, Inc. 2026 Equity Incentive Plan-Common Stock, par value $0.0001 per share |
| Amount Registered | shares | 6,286,841 |
| Proposed Maximum Offering Price per Unit | 16.31 |
| Maximum Aggregate Offering Price | $ 102,538,377.71 |
| Fee Rate | 0.01381% |
| Amount of Registration Fee | $ 14,160.55 |
| Offering Note | (1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended, this Registration Statement on Form S-8 (the "Registration Statement") shall also cover shares of the Registrant's common stock that become issuable under the Plans to prevent dilution as a result of any stock dividend, stock split, recapitalization or similar transaction. (2) Represents 6,286,841 shares of common stock reserved for future issuance under the Sarepta Therapeutics, Inc. 2026 Equity Incentive Plan. (3) Estimated solely for the purpose of determining the registration fee pursuant to Rule 457(c) and 457(h) under the Securities Act, the "proposed maximum offering price per share" is calculated based on the average of the high and low prices for the Registrant's common stock as reported on the Nasdaq Global Select Market on June 3, 2026. |
| Offering: 2 | |
| Offering: | |
| Fee Previously Paid | false |
| Other Rule | true |
| Security Type | Equity |
| Security Class Title | Sarepta Therapeutics, Inc. 2026 Employee Stock Purchase Plan-Common Stock, par value $0.0001 per share |
| Amount Registered | shares | 1,500,000 |
| Proposed Maximum Offering Price per Unit | 16.31 |
| Maximum Aggregate Offering Price | $ 24,465,000.00 |
| Fee Rate | 0.01381% |
| Amount of Registration Fee | $ 3,378.62 |
| Offering Note | (1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended, this Registration Statement on Form S-8 (the "Registration Statement") shall also cover shares of the Registrant's common stock that become issuable under the Plans to prevent dilution as a result of any stock dividend, stock split, recapitalization or similar transaction. (3) Estimated solely for the purpose of determining the registration fee pursuant to Rule 457(c) and 457(h) under the Securities Act, the "proposed maximum offering price per share" is calculated based on the average of the high and low prices for the Registrant's common stock as reported on the Nasdaq Global Select Market on June 3, 2026. (4) Represents 1,500,000 shares of common stock reserved for future issuance under the Sarepta Therapeutics, Inc. 2026 Employee Stock Purchase Plan. |